Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study

J Rheumatol. 2016 Aug;43(8):1475-9. doi: 10.3899/jrheum.151006. Epub 2016 Jun 15.

Abstract

Objective: To evaluate the rates of retention and discontinuation of adalimumab (ADA) due to efficacy and safety in Japanese patients with rheumatoid arthritis (RA).

Methods: All patients with RA (n = 476) who were treated with ADA in the Tsurumai Biologics Communication Registry were enrolled.

Results: The retention rate of ADA was 46% at 5 years. When focusing on insufficient efficacy, previous biologics use and high baseline disease activity were significant risk factors for up to 1 year. Methotrexate (MTX) use was a significantly low risk factor after 1 year of treatment.

Conclusion: Concomitant MTX contributes to the longterm efficacy of ADA therapy.

Keywords: ADALIMUMAB; DISCONTINUATION; EFFICACY; RETENTION RATE; RHEUMATOID ARTHRITIS; SAFETY.

MeSH terms

  • Adalimumab / adverse effects*
  • Adalimumab / therapeutic use
  • Adult
  • Aged
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / drug therapy*
  • Female
  • Humans
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Patient Dropouts*
  • Registries
  • Risk Factors
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Adalimumab
  • Methotrexate